Abstracts tagged "Atherosclerosis"

Abstract Number: 0599 • ACR Convergence 2025
Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Aakash V. Patel¹, Lingxiao Zhang², Emily S. Lau³, Baijun Zhou², Yuqing Zhang⁴, Hyon K. Choi⁵ and April Jorge⁶, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Quincy, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Massachusetts General Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with up to a three-fold increased risk of myocardial infarction (MI) and stroke. Statins have well-established cardioprotective benefits…
Abstract Number: 0458 • ACR Convergence 2025
TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Jesus Alberto Cardenas-de la Garza⁵, Iris J. Colunga-Pedraza³, Jose R Azpiri-Lopez⁶, Dionicio A. Galarza-Delgado³, Victor M Fraga-Enriquez⁷ and Diego Azamat Salcedo Almanza⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁸Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The Triglyceride-Glucose-BMI index (TyG-BMI) is a reliable method for detecting insulin resistance (IR), with effectiveness comparable to the gold standard. Elevated TyG-BMI levels have…
Abstract Number: 0425 • ACR Convergence 2025
High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease
Tahnee Spoden¹, Samira Nazzar Romero², Deborah McCurdy³, Alice Hoftman⁴, Sangmee Bae⁵, Jennifer Wang⁴, Ani Shahbazian⁴ and Christina Charles-Schoeman⁶, ¹UCLA, Los Angeles, CA, ²Nemours Children's Health, Orlando, ³UCLA Medical Center, Los Angeles, CA, ⁴UCLA, Los Angeles, ⁵UCLA Rheumatology, Los Angeles, CA, ⁶UCLA Medical Center, Santa Monica, CA
Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity…
Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Avanika Mahajan¹, Caroyln Harvey², Andy Abril³ and Megan Sullivan⁴, ¹Mayo Clinic, Scottsdale, ²Mayo Clinic, Phoenix, AZ, ³Mayo Clinic Florida, Jacksonville, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
Abstract Number: 2009 • ACR Convergence 2025
Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
Patrick Williamson¹, Rouhin Sen² and Angelo Gaffo³, ¹Tinsley Harrison Internal Medicine Residency, Department of Medicine, University of Alabama at Birmingham, Birmingham, ²University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology & Rheumatology, Birmingham, ³Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL
Background/Purpose: Gout is associated with a 50% increased risk of cardiovascular disease (CVD).1 The current recommendation for evaluating CVD risk in gout is to use…
Abstract Number: 1955 • ACR Convergence 2025
Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
George Karpouzas¹, Frederik Enevoldsen², Dzenan Masic², Matthew Budoff¹, Ellen-Margrethe Hauge² and Sarah Ormseth³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Aarhus University, Aarhus, Denmark, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: The composition of fat around the coronary arteries is evaluated as pericoronary adipose tissue attenuation (PCATa) on coronary CT-angiogram (CCTA). In general patients PCATa…
Abstract Number: 1950 • ACR Convergence 2025
Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
Frederik Enevoldsen¹, Sarah Ormseth², Dzenan Masic¹, Matthew Budoff³, Ellen-Margrethe Hauge¹ and George Karpouzas³, ¹Aarhus University, Aarhus, Denmark, ²The Lundquist Institute for Biomedical Innovation, Torrance, CA, ³Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Pericoronary adipose tissue attenuation (PCATa) reflects the composition of the fat directly surrounding the coronary arteries and is associated with coronary wall inflammation. In…
Abstract Number: 1845 • ACR Convergence 2025
Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Noe Macias-Segura¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) significantly increases the risk of premature atherosclerosis, contributing to long-term morbidity and mortality. Traditional cardiovascular risk factors do not fully…
Abstract Number: 1740 • ACR Convergence 2025
A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
Emily Chong¹, Kavya Sugur², Sophia Matossian¹, Katarina Kmetova³, Christine Goudsmit⁴, Jessica Turnier⁵ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Saline, MI
Background/Purpose: Adults with dermatomyositis face a well-established 2–3-fold increased risk of major adverse cardiovascular events, driven by systemic inflammation, endothelial dysfunction, and treatment-related metabolic complications.…
Abstract Number: 1528 • ACR Convergence 2025
Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
Esteban C. Garza-Gonzalez¹, Fernanda M. Garcia-Garcia², Oscar Azael Garza-Flores³, Rebeca L. Polina-Lugo⁴, Leslie Y. Lopez-Cantú², Jose R Azpiri-Lopez⁵, Iris J. Colunga-Pedraza², Jesus Alberto Cardenas-de la Garza⁶, Dionicio A. Galarza-Delgado² and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…
Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Aretha On¹, Xiwei Yang¹, Shae Chambers², Hammad Ali³, Touraj Khosravi-Hafshejani³, Lais Lopes Almeida Gomes², Rui Feng⁴, Kevin Jon Williams⁵ and Victoria Werth⁶, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA, Philadelphia, PA, ⁶University of Pennsylvania, Wynnewood, PA
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…
Abstract Number: 1331 • ACR Convergence 2025
Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Changes in serum cholesterol loading capacity (CLC) on macrophages were linked to coronary plaque progression in rheumatoid arthritis (RA). Inflammation, LDL oxidation and autoantibodies…
Abstract Number: 1330 • ACR Convergence 2025
Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens associate with cardioprotective benefits in the general population. Yet, dual pro- and anti-inflammatory effects were described in autoimmune states depending on concentration,…
Abstract Number: 1008 • ACR Convergence 2025
Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Hasan Satis¹, Umut Kalyoncu², Gizem Ayan³, Ali Aykut Fidanci⁴, Mustafa Mahir Ulgu⁴, Naim Ata⁴, Suayip Birinci⁴, Mehmet Koçak⁵ and Ahmet Gul⁶, ¹University of Health Sciences, Abdurrahman Yurtaslan Oncology Hospital, Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Ministry of Health, Ankara, Turkey, ⁵Medipol University, Istanbul, Turkey, ⁶Istanbul University, Istanbul, Turkey
Background/Purpose: While two trials with colchicine have demonstrated its efficacy in reducing the risk of cardiovascular events, a more recent study showed no significant impact…
Abstract Number: 0614 • ACR Convergence 2025
Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Ileana C. Reynosa-Silva¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Aleydis Gonzalez-Melendez¹, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁴, Rosa Arvizu-Rivera⁵, Jesus Alberto Cardenas-de la Garza⁶ and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with an elevated risk of cardiovascular (CV) disease, largely due to chronic inflammation and…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].